News and Publications

Penningtons Manches Cooper advises Oxford Endovascular on £8 million funding round

Posted: 30/05/2024

The corporate team at Penningtons Manches Cooper has advised Oxford University spin-out Oxford Endovascular Ltd on securing its £8 million Series A+ funding round led by Parkwalk.

Oxford Endovascular, founded in 2015, is a medtech start-up pioneering an innovative method using origami-inspired techniques to prevent brain haemorrhages through the treatment of intracranial aneurysms, a condition that affects 1 in 50 people.

This recent funding will assist in advancing Oxford Endovascular’s medical device, OXIFLOW, towards a first-in-human clinical study. The potential market for devices designed to address brain aneurysms is nearing an annual value of $3 billion.

The client team was led by corporate partner James Went and associate Leo Shrimpton, and also included corporate tax partner Kathy Potter.

Mike Karim, CEO of Oxford Endovascular, said: “This investment further enables Oxford Endovascular's aspiration to transform brain aneurysm treatment and further develops us as a leading medtech company in the UK. I would like to thank the Penningtons Manches Cooper team for its continued support – having James and Leo on our side was invaluable."

James Went commented: “We are delighted to have supported longstanding client Oxford Endovascular, contributing to the success of this latest funding round as the company progresses this much needed technology.”

Arrow GIFReturn to news headlines

Penningtons Manches Cooper LLP

Penningtons Manches Cooper LLP is a limited liability partnership registered in England and Wales with registered number OC311575 and is authorised and regulated by the Solicitors Regulation Authority under number 419867.

Penningtons Manches Cooper LLP